Pancreatic cancer 1

Common Name(s)

Pancreatic cancer 1

Description for this condition is not yet available.
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Pancreatic cancer 1" for support, advocacy or research.

Logo
Pancreatic Cancer Action Network

The Pancreatic Cancer Action Network is a nationwide network of people dedicated to working together to advance research, support patients and create hope for those affected by pancreatic cancer.

Last Updated: 20 Feb 2013

View Details

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
Top

How do you compare to others with this condition?

Privately answer questions about your health. Let resources, you select, come to you.

Anonymously share and see how your answers compare with others with this condition while privately providing key pieces of information to medical researchers, disease advocacy groups, and others ONLY YOU select to help speed up cures and better alternatives.

 
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Pancreatic cancer 1" for support, advocacy or research.

Logo
Pancreatic Cancer Action Network

The Pancreatic Cancer Action Network is a nationwide network of people dedicated to working together to advance research, support patients and create hope for those affected by pancreatic cancer.

http://www.pancan.org

Last Updated: 20 Feb 2013

View Details

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
 
 
Top

Scientific Literature

Articles from the PubMed Database

Research articles describe the outcome of a single study. They are the published results of original research.
The terms "Pancreatic cancer 1" returned 304 free, full-text research articles on human participants. First 3 results:

Targeting the insulin growth factor-1 receptor with fluorescent antibodies enables high resolution imaging of human pancreatic cancer in orthotopic mouse models.
 

Author(s): Jeong Youp Park, Jin Young Lee, Yong Zhang, Robert M Hoffman, Michael Bouvet

Journal: Oncotarget. 2016 Apr;7(14):18262-8.

 

The goal of the present study was to determine whether insulin-like growth factor-1 receptor (IGF-1R) antibodies, conjugated with bright fluorophores, could enable visualization of pancreatic cancer in orthotopic nude mouse models. IGF-1R antibody (clone 24-31) was conjugated with ...

Last Updated: 14 Jul 2016

Go To URL
Polycomb complex protein BMI-1 promotes invasion and metastasis of pancreatic cancer stem cells by activating PI3K/AKT signaling, an ex vivo, in vitro, and in vivo study.
 

Author(s): Min-Cong Wang, Min Jiao, Tao Wu, Li Jing, Jie Cui, Hui Guo, Tao Tian, Zhi-ping Ruan, Yong-Chang Wei, Li-Li Jiang, Hai-Feng Sun, Lan-Xuan Huang, Ke-Jun Nan, Chun-Li Li

Journal: Oncotarget. 2016 Feb;7(8):9586-99.

 

Cancer stem cell theory indicates cancer stem cells are the key to promote tumor invasion and metastasis. Studies showed that BMI-1 could promote self-renew, differentiation and tumor formation of CSCs and invasion/metastasis of human cancer. However, whether BMI-1 could regulate ...

Last Updated: 14 Apr 2016

Go To URL
CXCR2 signaling regulates KRAS(G¹²D)-induced autocrine growth of pancreatic cancer.
 

Author(s): Abhilasha Purohit, Michelle Varney, Satyanarayana Rachagani, Michel M Ouellette, Surinder K Batra, Rakesh K Singh

Journal: Oncotarget. 2016 Feb;7(6):7280-96.

 

Pharmacological inhibition of RAS, the master regulator of pancreatic ductal adenocarcinoma (PDAC), continues to be a challenge. Mutations in various isoforms of RAS gene, including KRAS are known to upregulate CXC chemokines; however, their precise role in KRAS-driven pancreatic ...

Last Updated: 27 Mar 2016

Go To URL

Reviews from the PubMed Database

Review articles summarize what is currently known about a disease. They discuss research previously published by others.
The terms "Pancreatic cancer 1" returned 6 free, full-text review articles on human participants. First 3 results:

Gemcitabine Compared With Gemcitabine and S-1 Combination Therapy in Advanced Pancreatic Cancer: A Systematic Review and Meta-Analysis.
 

Author(s): Doudou Li, Changhao Chen, Yu Zhou, Rufu Chen, Xinxiang Fan, Zhuofei Bi, Zhihua Li, Yimin Liu

Journal: Medicine (Baltimore). 2015 Sep;94(35):e1345.

 

Several reports suggest that gemcitabine (GEM) plus S-1 combination (GS) is associated to prolong the survival in patients with unresectable pancreatic cancer (PC). We conducted a systemic review and meta-analysis of studies comparing the safety and efficacy of GS versus GEM.Summary ...

Last Updated: 4 Sep 2015

Go To URL
S-1 in the treatment of pancreatic cancer.
 

Author(s): Kentaro Sudo, Kazuyoshi Nakamura, Taketo Yamaguchi

Journal: World J. Gastroenterol.. 2014 Nov;20(41):15110-8.

 

S-1 is an oral 5-fluorouracil (5-FU) prodrug, which is designed to improve the antitumor activity of 5-FU by inhibiting dihydropyrimidine dehydrogenase, the key enzyme of 5-FU catabolism. Recently, two important studies on the clinical use of S-1 for pancreatic cancer have been reported ...

Last Updated: 11 Nov 2014

Go To URL
Involvement of substance P and the NK-1 receptor in pancreatic cancer.
 

Author(s): Miguel Muñoz, Rafael Coveñas

Journal: World J. Gastroenterol.. 2014 Mar;20(9):2321-34.

 

Pancreatic cancer is the fourth leading cause of cancer related-death for both men and women and the 1- and 5-year relative survival rates are 25% and 6%, respectively. Thus, it is urgent to investigate new antitumor drugs to improve the survival of pancreatic cancer patients. The ...

Last Updated: 7 Mar 2014

Go To URL
 
 
Top

Symptoms, Diagnosis, and Treatment

There are currently no related results available in GeneReviews.

 
 
Top

Clinical Trial Information This information is provided by ClinicalTrials.gov

Screening for PDAC in BRCA1/2 Patients
 

Status: Recruiting

Condition Summary: Pancreatic Cancer

 

Last Updated: 8 Apr 2016

Go to URL
Adjuvant Gemcitabine Versus 5-FU/Leucovorin Based on hENT1 Immunostaining
 

Status: Recruiting

Condition Summary: Pancreatic Cancer

 

Last Updated: 4 Sep 2016

Go to URL
Nimotuzumab Plus S1 Versus Placebo Plus S1 as Maintenance Treatment in Patients With Unresectable Pancreatic Cancer
 

Status: Not yet recruiting

Condition Summary: Unresectable Pancreatic Cancer

 

Last Updated: 25 Oct 2016

Go to URL